Altogether, these findings suggest that targeting glucose metabolism through the combined inhibition of the Rb/E2F/c-myc axis and the PI3K/AKT/mTOR signaling may contribute to the anti-tumor efficacy of palbociclib-PI3K/mTOR inhibitors combinations in MPM cells. This evidence concerns the gene MYC and neoplasm.